Page 152 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 6a
Supplemental Table 6. Uni- and multivariable Cox Proportional Hazard analyses of ∆SUVmax analysis-
group for 2-year OS (n=367).
Age (≤60 vs >60)
aaIPI (low/low-intermediate vs high-intermediate/high)
B symptoms (no vs yes)
∆SUVmax (>70% vs ≤70%)
Gender (male vs female)
Treatment arm (R-CHOP14 vs RR- CHOP14
* Statistically significant difference
2-year OS
1·65 (0·88-3·08) 2·85 (1·47-5·52)
2·12 (1·23-3·65) 5·52 (3·10-9·83) 0·68 (0·40-1·18) 1·01 (0·59-1·72)
0·116 1·92 (1·01-3·62) 0·0002* 2·42 (1·24-4·76)
0·0007* 1·82 (1·01-3·16) <0·0001* 6·03 (3·36-10·81) 0·172 0·55 (0·31-0·95) 0·969
0·046* 0·010*
0·036* <0·0001* 0·034*
Univariate P-value Multivariable P-value HR (95%CI) HR (95%CI)
Abbreviations: 95%CI= 95% confidence interval; aaIPI= age-adjusted international prognostic index; ∆SUVmax= reduction of maximum standardized uptake value between baseline and interim 18F-FDG PET(/CT); HR= Hazard Ratio; OS= overall survival.
Supplemental Table 7. Uni- and multivariable Cox Proportional Hazard analyses including baseline MTV for 2-year OS (n=296).
Age (≤60 vs >60)
aaIPI (low/low-intermediate vs high- intermediate/high)
B symptoms (no vs yes)
Baseline MTV log-transformed
∆SUVmax (>70% vs ≤70%)
Gender (male vs female)
Treatment arm (R-CHOP14 vs RR- CHOP14
* Statistically significant difference
2-year OS
1·36 (0·70-2·62) 2·43 (1·20-4·91)
2·15 (1·19-3·91) 1·62 (1·25-2·08) 7·33 (3·97-13·55) 0·67 (0·37-1·21) 0·97 (0·54-1·74)
0·367 0·013*
0·012*
0·0002* 1·55 (1·20-2·00) <0·0001* 6·75 (3·63-12·55) 0·182
0·923
0·001* <0·0001*
Univariate P-value Multivariable P-value HR (95%CI) HR (95%CI)
Abbreviations: 95%CI= 95% confidence interval; aaIPI= age-adjusted international prognostic index; HR= Hazard Ratio; MTV=metabolic tumor volume; OS= overall survival.
150